Status: Recruiting
A Phase 1/1b Study of IAM1363 in HER2 Cancers
This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.
Participants needed: 383
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Iambic Therapeutics, IncUpdated: Jun 4, 2026Locations: 53
Eligibility criteria
Age ≥ 18 years [+7]
Clinically significant cardiac disease [+8]